MannKind Corporation's Awesomely Imperfect 2013

Any time a biotech like MannKind Corporation (NASDAQ: MNKD  ) ends the year with stock more than double where it started, it's hard to call it anything but successful.

But it could have been even better.

MNKD Chart

MNKD data by YCharts.

MannKind is the perfect example of premature valuation. Investors rush into the stock as clinical trial data becomes imminent and the stock has no place to go from there but down.

The run-up in the first half of the year came in anticipation of the release of  two phase 3 trials required by the Food and Drug Administration to approve the Dreamboat inhaler for MannKind's insulin Afrezza.

Clinical trials with a slightly larger inhaler already showed that the inhaled insulin was capable of lowering blood sugar levels, so the trials seemed fairly low risk, attracting investors in the process.

Positive results, temporary spike
MannKind popped in August following positive results for the two phase 3 trials. The drug and device did exactly what was expected -- nothing less, but not much more, either. In one of the trials, Afrezza was shown to be noninferior to -- biotech speak for "just as good as" -- Novo Nordisk's (NYSE: NVO  ) injected insulin NovoLog. However, a larger percentage of the patients taking Novo Nordisk's drug hit their target levels of A1c -- a long-term measure of blood sugar levels -- than those taking MannKind's drug.

Nevertheless MannKind saw a double-digit increase following the results. I questioned the valuation at that point, which turned out to be a very good call. MannKind is off its high of the year by 40%. There wasn't any major news since the phase 3 trial results were presented in August; the move seems to be entirely due to investors selling the news. The current valuation of $1.5 billion looks reasonable. There's plenty of upside available, but also questions over whether MannKind can get there.

Getting back
While the phase 3 data wasn't out-of-this-world good, it was plenty good enough to get the drug approved. Just the anticipation of Afrezza's approval could be enough to send the stock higher, as we saw with the phase 3 data. The response to the last rejection has already been submitted, putting an approval decision on or before April 15 if the FDA sticks to its internal goal.

To reach its full potential, investors will need to be convinced that MannKind can not only get Afrezza approved, but that it'll be able to compete with NovoLog and Eli Lilly's (NYSE: LLY  ) injected insulin Humalog. Avoiding injections is certainly a huge selling point, but it's also a potential negative since doctors are generally skeptical of delivering drugs via the lungs for diseases that don't affect the lungs.

Announcing a marketing partnership with a large up-front payment would go a long ways toward convincing investors that Afrezza can take market share from Novo Nordisk and Eli Lilly. An endorsement by a big diabetes player would be a good sign that the market potential is as big as MannKind thinks it is.

Our top pick for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 25, 2013, at 1:32 AM, Alex45 wrote:

    I found your comment that "doctors are generally skeptical about of delivering drugs via the lungs for diseases that don't affect the lungs," very interesting.

    As a doctor, I can say that you are largely correct, however everyone from doctors to smokers to drug addicts can tell you that inhaled medications can have immediate and profound systemic effects. Doctors will be able to get past prescribing inhaled medications so long as it can be adequately demonstrated that there are no adverse side effects. Additionally, doctors will have to be aggressively educated about how to dose these new medications (we are already comfortable with injectable insulin, why change?)

    A non-injectable insulin will appeal to patients, and patient pressure on doctors will undoubtedly make this medication wildly popular (at least to those with insurance). It's not so much giving the tiny injection that is difficult for patients, but measuring and drawing up medication into syringes. This was helped to a certain extent with the invention of insulin pens. I think the main benefit would be to patients that cannot properly prepare their medications (i.e. elderly, disabled and children). This will not alleviate the need for finger stick testing of blood sugar, which hurts much more than the insulin injections! Show me the company that eliminates the needs for those, and I will invest heavily.

  • Report this Comment On December 27, 2013, at 10:45 AM, larryw101 wrote:

    Foolish article and foolish title. This is just a rehash of old events. No real substance or perspective.

    Where does Motley find these bozo kids who write for them? They write for their penny a click commission and that's it. Believe me. Where are this author's credentials? He has none....... I rest my case.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2775428, ~/Articles/ArticleHandler.aspx, 8/20/2014 8:48:44 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement